FP14.11 Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 StudyCaicun Zhou, Li Mao, C. Su et al.|Journal of Thoracic Oncology|2021Cited by 5